| scholarly article | Q13442814 |
| P2093 | author name string | K. R. Lynch | |
| T. L. Macdonald | |||
| A. M. Schreihofer | |||
| Y. V. Mukhin | |||
| B. H. Heasley | |||
| C. E. Heise | |||
| W. L. Santos | |||
| P2860 | cites work | Molecular cloning and characterization of a novel human G-protein-coupled receptor, EDG7, for lysophosphatidic acid | Q22010389 |
| Edg-6 as a putative sphingosine 1-phosphate receptor coupling to Ca(2+) signaling pathway | Q22253210 | ||
| Molecular cloning of the human Edg2 protein and its identification as a functional cellular receptor for lysophosphatidic acid | Q24309021 | ||
| Sphingosine-1-Phosphate as a Ligand for the G Protein-Coupled Receptor EDG-1 | Q24314828 | ||
| Identification of cDNAs encoding two G protein‐coupled receptors for lysosphingolipids1 | Q24316056 | ||
| Characterization of a Novel Subtype of Human G Protein-coupled Receptor for Lysophosphatidic Acid | Q24321223 | ||
| Ventricular zone gene-1 (vzg-1) encodes a lysophosphatidic acid receptor expressed in neurogenic regions of the developing cerebral cortex | Q24321349 | ||
| Characterization of a novel sphingosine 1-phosphate receptor, Edg-8 | Q28143704 | ||
| A rat G protein-coupled receptor selectively expressed in myelin-forming cells | Q28569876 | ||
| The molecular pharmacology of lysophosphatidate signaling | Q30305675 | ||
| Lysophosphatidic acid-induced mitogenesis is regulated by lipid phosphate phosphatases and is Edg-receptor independent. | Q30306254 | ||
| Characterization of a Receptor Subtype-Selective Lysophosphatidic Acid Mimetic | Q30471683 | ||
| Transfer of purified herpes virus thymidine kinase gene to cultured mouse cells | Q34017706 | ||
| LPA: a novel lipid mediator with diverse biological actions | Q35632934 | ||
| Lysophosphatidic acid signalling | Q40444988 | ||
| Decanoyl lysophosphatidic acid induces platelet aggregation through an extracellular action. Evidence against a second messenger role for lysophosphatidic acid | Q42866943 | ||
| Effects of synthetic and natural lysophosphatidic acids on the arterial blood pressure of different animal species | Q44500797 | ||
| N-palmitoyl-serine and N-palmitoyl-tyrosine phosphoric acids are selective competitive antagonists of the lysophosphatidic acid receptors. | Q50760286 | ||
| Human platelet aggregation induced by 1-alkyl-lysophosphatidic acid and its analogs: a new group of phospholipid mediators? | Q71965824 | ||
| Biochemical characterization of the interaction of lipid phosphoric acids with human platelets: comparison with platelet activating factor | Q72519053 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1173-1180 | |
| P577 | publication date | 2001-12-01 | |
| P1433 | published in | Molecular Pharmacology | Q1943386 |
| P1476 | title | Activity of 2-substituted lysophosphatidic acid (LPA) analogs at LPA receptors: discovery of a LPA1/LPA3 receptor antagonist | |
| Activity of 2-Substituted Lysophosphatidic Acid (LPA) Analogs at LPA Receptors: Discovery of a LPA1/LPA3 Receptor Antagonist | |||
| P478 | volume | 60 |
| Q33548210 | 2D binary QSAR modeling of LPA3 receptor antagonism |
| Q34199719 | ATX-LPA receptor axis in inflammation and cancer |
| Q34339759 | Aiming drug discovery at lysophosphatidic acid targets |
| Q40063948 | Alkoxymethylenephosphonate analogues of (Lyso) phosphatidic acid stimulate signaling networks coupled to the LPA2 receptor |
| Q41954435 | Alpha-substituted phosphonate analogues of lysophosphatidic acid (LPA) selectively inhibit production and action of LPA |
| Q37685105 | Calcium Signaling of Lysophosphatidylethanolamine through LPA1 in Human SH-SY5Y Neuroblastoma Cells |
| Q38035634 | Current progress in non-Edg family LPA receptor research |
| Q30439954 | Engineering vascularized tissues using natural and synthetic small molecules |
| Q84746759 | First-in-class antifibrotic therapy targeting type 1 lysophosphatidic acid receptor |
| Q33610285 | Identification of heparin-binding EGF-like growth factor (HB-EGF) as a biomarker for lysophosphatidic acid receptor type 1 (LPA1) activation in human breast and prostate cancers |
| Q30429523 | International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid receptor nomenclature |
| Q40633092 | Ki16425, a Subtype-Selective Antagonist for EDG-Family Lysophosphatidic Acid Receptors |
| Q46228136 | LPA1 receptor-mediated thromboxane A2 release is responsible for lysophosphatidic acid-induced vascular smooth muscle contraction |
| Q37503698 | Lysophosphatidic acid induces vasodilation mediated by LPA1 receptors, phospholipase C, and endothelial nitric oxide synthase |
| Q42021207 | Lysophosphatidic acid receptor agonists and antagonists (WO2010051053) |
| Q30573574 | Lysophosphatidic acid receptor type 1 (LPA1) plays a functional role in osteoclast differentiation and bone resorption activity. |
| Q42716792 | Lysophosphatidic acid stimulates epidermal growth factor‐family ectodomain shedding and paracrine signaling from human lung fibroblasts |
| Q28294232 | Lysophosphatidylethanolamine utilizes LPA1 and CD97 in MDA-MB-231 breast cancer cells |
| Q36930850 | Lysophospholipid interactions with protein targets |
| Q34025135 | Lysophospholipid receptor nomenclature review: IUPHAR Review 8. |
| Q34691601 | Molecular basis for lysophosphatidic acid receptor antagonist selectivity |
| Q35559631 | Molecular mechanisms of lysophosphatidic acid action |
| Q39619856 | Pharmacokinetic and Pharmacodynamic Characterization of an Oral Lysophosphatidic Acid Type 1 Receptor-Selective Antagonist |
| Q30410634 | Pharmacological tools for lysophospholipid GPCRs: development of agonists and antagonists for LPA and S1P receptors |
| Q40246564 | Phosphorothioate analogues of alkyl lysophosphatidic acid as LPA3 receptor-selective agonists |
| Q35551835 | Regulation of Mammalian Physiology, Development, and Disease by the Sphingosine 1-Phosphate and Lysophosphatidic Acid Receptors |
| Q91654129 | Regulation of tumor cell - Microenvironment interaction by the autotaxin-lysophosphatidic acid receptor axis |
| Q33786333 | Role of LPAR3, PKC and EGFR in LPA-induced cell migration in oral squamous carcinoma cells |
| Q38026693 | Role of sphingosine 1-phosphate and lysophosphatidic acid in fibrosis |
| Q43809125 | Selective Ligands for Lysophosphatidic Acid Receptor Subtypes: Gaining Control over the Endothelial Differentiation Gene Family |
| Q37407372 | Structure-based drug design identifies novel LPA3 antagonists |
| Q30486707 | The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors |
| Q28191543 | The emerging role of lysophosphatidic acid in cancer |
| Q46861210 | The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak |
| Q34687134 | The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases |
Search more.